Login / Signup

[Treatment of toxic hepatitis in COVID-19 patients].

Igor MaevR I ShaburovA I PavlovA I MolodovaA G KarakozovS P KazakovE G LebedevaA F IvolginM N EreminO B Levchenko
Published in: Terapevticheskii arkhiv (2023)
The use of drugs with hepatoprotective effect in the form of monotherapy in groups 1 (UDCA) and 2 (ademethionine) showed a low therapeutic effect with positive dynamics of clinical and laboratory indicators of toxic hepatitis activity. The use of combined treatment in group 3 (UDCA and ademethionine) demonstrated the maximum therapeutic effect, pronounced positive dynamics in the form of normalization of clinical and laboratory indicators of toxic hepatitis activity.
Keyphrases
  • sars cov
  • combination therapy